Viatris (VTRS) Other Non-Current Assets (2019 - 2026)
Viatris (VTRS) recorded quarterly Other Non-Current Assets of $1.1 billion in Q1 2026, down 40.92% quarter-over-quarter from $1.9 billion in Q4 2025, and down 51.38% on a YoY basis from $2.3 billion in Q1 2025.
Viatris (VTRS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 51.38% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 51.38% YoY), while the FY2025 annual figure was $1.9 billion, down 20.58% from the prior year.
- Other Non-Current Assets was $1.1 billion for Q1 2026 at Viatris, down from $1.9 billion in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.5 billion in Q3 2024 to a low of $230.3 million in Q4 2022.
- Historically, Other Non-Current Assets has averaged $1.8 billion across 5 years, with a median of $2.2 billion in 2023.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets surged 859.05% in 2023, then sank 51.38% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $230.3 million in 2022, then soared by 859.05% to $2.2 billion in 2023, then climbed by 6.71% to $2.4 billion in 2024, then declined by 20.58% to $1.9 billion in 2025, then plunged by 40.92% to $1.1 billion in 2026.
- The last three Other Non-Current Assets figures came in at $1.1 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 47.63 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Viatris | - | - | 1.16 Bn | 1.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 1.87 Bn |
| Sep 30, 2025 | 1.89 Bn |
| Jun 30, 2025 | 2.00 Bn |
| Mar 31, 2025 | 2.27 Bn |
| Dec 31, 2024 | 2.36 Bn |
| Sep 30, 2024 | 2.47 Bn |
| Jun 30, 2024 | 2.45 Bn |
| Mar 31, 2024 | 2.23 Bn |
| Dec 31, 2023 | 2.21 Bn |
| Sep 30, 2023 | 2.40 Bn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.42 Bn |
| Dec 31, 2022 | 230.30 Mn |
| Sep 30, 2022 | 963.90 Mn |
| Jun 30, 2022 | 997.40 Mn |
| Mar 31, 2022 | 1.06 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.03 Bn |
| Mar 31, 2021 | 1.02 Bn |